Cargando…

Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial

The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia https://bit.ly/3tEQo3p

Detalles Bibliográficos
Autores principales:	Agustí, Alvar, De Stefano, Gaston, Levi, Alberto, Muñoz, Xavier, Romero-Mesones, Christian, Sibila, Oriol, Lopez-Giraldo, Alejandra, Plaza Moral, Vicente, Curto, Elena, Echazarreta, Andrés L., Márquez, Silvana E., Pascual-Guàrdia, Sergi, Santos, Salud, Marin, Alicia, Valdés, Luis, Saldarini, Fernando, Salgado, Clara, Casanovas, Georgina, Varea, Sara, Ríos, José, Faner, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832375/ https://www.ncbi.nlm.nih.gov/pubmed/35144989 http://dx.doi.org/10.1183/13993003.03036-2021

Ejemplares similares

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
por: Agusti, Alvar, et al.
Publicado: (2021)

Molecular Interactions of SARS-CoV-2 in Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease
por: Agusti, Alvar, et al.
Publicado: (2021)

Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?
por: Halpin, David M G, et al.
Publicado: (2020)

Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
por: Cruz, Tamara, et al.
Publicado: (2023)

When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary Disease
por: Agusti, Alvar, et al.
Publicado: (2020)

SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae
por: Cruz, Tamara, et al.
Publicado: (2022)

From systems biology to P4 medicine: applications in respiratory medicine
por: Noell, Guillaume, et al.
Publicado: (2018)

COVID-19 and lung involvement
por: You, Jin-Seok, et al.
Publicado: (2022)

Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge
por: Sibila, Oriol, et al.
Publicado: (2022)

Reply to Guo et al.
por: Wang, Gang, et al.
Publicado: (2023)

Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge
por: Sibila, Oriol, et al.
Publicado: (2021)

Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD
por: López-Giraldo, Alejandra, et al.
Publicado: (2018)

Systemic Inflammatory Response to Smoking in Chronic Obstructive Pulmonary Disease: Evidence of a Gender Effect
por: Faner, Rosa, et al.
Publicado: (2014)

Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD
por: Casas-Recasens, Sandra, et al.
Publicado: (2021)

Low birth weight as a potential risk factor for severe COVID-19 in adults
por: Crispi, Fàtima, et al.
Publicado: (2021)

Real-life burden of hospitalisations due to COPD exacerbations in Spain
por: Izquierdo, José Luis, et al.
Publicado: (2022)

Cellular Senescence in Lung Fibrosis
por: Hernandez-Gonzalez, Fernanda, et al.
Publicado: (2021)

Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity
por: Perea, Lídia, et al.
Publicado: (2020)

Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD)
por: Cruz, Tamara, et al.
Publicado: (2019)

Validity of prognostic models of critical COVID-19 is variable. A systematic review with external validation
por: Cárdenas-Fuentes, Gabriela, et al.
Publicado: (2023)

Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study
por: Mendoza, Nuria, et al.
Publicado: (2021)

Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations
por: Shafiek, Hanaa, et al.
Publicado: (2015)

An investigation of the resolution of inflammation (catabasis) in COPD
por: Noguera, Aina, et al.
Publicado: (2012)

Inhaled corticosteroids for the treatment of COVID-19
por: Bafadhel, Mona, et al.
Publicado: (2022)

Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients
por: Millares, Laura, et al.
Publicado: (2019)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Estudio histológico mediante biopsia pulmonar post mortem en pacientes con neumonía por COVID-19
por: Sellarés, Jacobo, et al.
Publicado: (2022)

[Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia
por: Sellarés, Jacobo, et al.
Publicado: (2022)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis
por: Faner, Rosa, et al.
Publicado: (2019)

Network medicine analysis of COPD multimorbidities
por: Grosdidier, Solène, et al.
Publicado: (2014)

Treatable traits in the NOVELTY study
por: Agustí, Alvar, et al.
Publicado: (2022)

Budesonide and fluticasone and adrenal suppression
por: Fouda, Mona A, et al.
Publicado: (2012)

Eosinophilic cholangitis treatment with budesonide
por: De Roza, Marianne Anastasia, et al.
Publicado: (2017)

The EASI model: A first integrative computational approximation to the natural history of COPD
por: Agustí, Alvar, et al.
Publicado: (2017)

The inflammasome pathway in stable COPD and acute exacerbations
por: Faner, Rosa, et al.
Publicado: (2016)

Use of Budesonide in the Treatment of Microscopic Colitis
por: Tangri, Vikram, et al.
Publicado: (2010)

Continuous flow process for preparing budesonide
por: Phull, Manjinder Singh, et al.
Publicado: (2022)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Characterisation and prognosis of undiagnosed chronic obstructive pulmonary disease patients at their first hospitalisation
por: Balcells, Eva, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kiifdn6p4a3qtmmhllsfdub23s